The study, published in JAMA Network Open, examined outcomes among patients treated between 2023 and 2026. The analysis considered survival, liver function before and after treatment, and the risk of kidney injury. Early clinical studies supporting the Food and Drug Administration’s 2023 clearance of the procedure had reported encouraging technical effectiveness and safety in carefully selected patients, but the new review was designed to assess how histotripsy performed in broader clinical practice.

Histotripsy is a noninvasive treatment that uses focused sound waves to create air bubbles within diseased liver tissue. The bubbles destroy cancer cells, and the procedure is typically performed on an outpatient basis without a hospital stay. The approach is intended to treat liver tumors directly, without the incision required by surgery. The new findings indicate that the procedure itself was generally well tolerated: laboratory toxicity and procedural complications occurred at low rates, while liver function and kidney-injury outcomes were assessed as markers of treatment-related safety.

However, nearly 70% of the treatments in the analysis were performed in patients with metastatic cancer involving the liver, including some patients with pancreatic cancer. The researchers said this distribution raises questions about which patients with metastatic disease are most likely to benefit from a therapy directed specifically at liver tumors. They also emphasized that advanced cancer and overall disease burden may have contributed to the observed mortality, although the study cannot establish whether histotripsy caused any of the deaths. “That does not mean histotripsy caused those deaths,” said Allan Tsung, a surgical oncologist and chair of UVA Health’s Department of Surgery. “What it does tell us is that we need to better understand which patients are most likely to live long enough and have the right type of cancer to meaningfully benefit from this treatment.”

The authors said the timing of histotripsy therefore deserves careful consideration, especially for people with advanced disease and limited life expectancy. A procedure can be technically safe and still provide limited benefit if a patient’s cancer is too advanced for a liver-directed treatment to alter the broader course of illness. Tsung described the study’s broader implication in practical terms: the next question is not simply whether histotripsy can be performed, but when it should be performed and for whom. The analysis was observational and did not determine that the procedure caused the deaths or establish that histotripsy improved survival. Instead, it provides a real-world safety snapshot and identifies patient selection and treatment timing as priorities for future evaluation. The research team included Olivia Sears, Elio R. Bitar, Kaelyn C. Cummins, Natalie Blatz, Maclean Cook, Daniel Sheeran and Tsung; the report noted that Sheeran had served on HistoSonics’ Prior Medical Advisory Board.

Subject of Research: Real-world safety and patient-selection outcomes of noninvasive histotripsy for liver tumors

Article Title: Review reveals real-world results of new, incisionless liver cancer treatment

Article References: Review reveals real-world results of new, incisionless liver cancer treatment. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: histotripsy, liver cancer, focused ultrasound, real-world evidence, metastatic disease, patient selection, treatment safety, clinical outcomes, Review, reveals, real-world, results

The editorial, authored by Gabriel Broocks of Helios Medical Center Schwerin and colleagues from Germany, Singapore, and the United States, synthesizes the current state of DMVO research across epidemiology, diagnostics, treatment options, and outcome prediction. Its central message is that DMVO is not a single disease entity. Occlusions differ in vessel diameter, anatomical segment, eloquence of the affected territory, collateral supply, clinical deficit severity, thrombus origin, and procedural accessibility. Primary DMVOs must also be distinguished from secondary distal occlusions that arise through spontaneous or treatment-related thrombus migration after an initially proximal occlusion. Treating all of these presentations as one therapeutic indication, the authors contend, has been a fundamental error in trial design.

Three randomized trials have now tested routine thrombectomy in broadly selected DMVO populations. DISTAL, ESCAPE-MeVO, and the early-terminated DISCOUNT trial did not demonstrate a clinical benefit of endovascular treatment and raised concerns regarding procedure-related harm, including symptomatic intracranial hemorrhage and, in some cohorts, mortality signals. These results sent shockwaves through the stroke community, prompting some to question whether distal thrombectomy should be abandoned altogether. But the story took a dramatic turn with ORIENTAL-MeVO, a trial conducted in Chinese patients with medium-vessel occlusion and moderate-to-severe deficits. Among participants with a National Institutes of Health Stroke Scale score of 6 or higher, endovascular treatment increased 90-day functional independence from 46.6 percent to 58.6 percent, with an adjusted rate ratio of 1.24 and a 95 percent confidence interval of 1.07 to 1.44. Symptomatic intracranial hemorrhage occurred in 4.7 percent of treated patients versus 2.2 percent of controls. This divergent result underscores the influence of trial population, occlusion definition, thrombolysis use, and procedural strategy, and argues powerfully against treating DMVO as a single therapeutic indication.

Neutral treatment effects should not be mistaken for a benign natural history. Across contemporary randomized control groups, between 32 and 53 percent of medically managed patients did not achieve functional independence at 90 days. This proportion exceeded 45 percent in DISTAL, at 45.3 percent, and in ORIENTAL-MeVO, at 53.4 percent. These control arms represent some of the most robust prospective repositories of outcome data under contemporary medical care, and they show that DMVO frequently results in death or persistent dependency. The observation does not justify indiscriminate thrombectomy, since technical accessibility alone does not establish a treatment indication and expected benefit must exceed procedural risk. But it does demonstrate that both routine endovascular treatment as tested and medical treatment alone remain unsatisfactory for many patients, reinforcing the urgent need for better selection and safer or more effective reperfusion strategies.

The trials, therefore, sharpen rather than settle the central question of patient selection, particularly for M2 occlusions, whose anatomical and functional definitions remain heterogeneous. Proximal or dominant M2 branches lie closer to classical large-vessel-occlusion evidence than truly distal M3, A3, or P3 occlusions. Observational data suggest that any benefit of successful reperfusion may concentrate in specific phenotypes. In M2 stroke, the association between recanalization and 90-day functional independence was larger at higher baseline stroke severity, according to a multicenter cohort study published in Neurology. Complementing this, penumbral imaging identified subgroups defined by larger hypoperfusion or penumbral volumes in which reperfusion was associated with better outcome, as reported in the journal Stroke. These hypothesis-generating findings support imaging- and severity-informed selection rather than a purely anatomical indication, suggesting that the future of DMVO treatment lies not in the catheter itself but in the brain imaging that determines who receives it.

Several contributions to the Research Topic address the delicate balance between reperfusion efficacy and vessel safety. A systematic review and meta-analysis by Loh and colleagues found that combined stent-retriever and aspiration techniques were associated with higher first-pass reperfusion and lower symptomatic intracranial hemorrhage than single-device approaches, although final functional outcomes were similar. These retrospective data concern technique selection among treated patients and do not establish superiority of thrombectomy over medical treatment. The ONE-SEG technique of Hamada and colleagues, which combines limited deployment of the distal basket segment of a stent retriever with aspiration, achieved high reperfusion rates in a small M2 cohort, with outcomes differing substantially between primary and secondary M2 occlusions. On the engineering side, Ishiguro and colleagues linked reduced radial and axial device forces to less vessel deformation on bench testing and a lower frequency of post-procedural subarachnoid hemorrhage. When the expected absolute benefit is small, such reductions in procedural trauma may prove decisive.

Newer low-profile devices may alter the procedural risk-benefit balance, although their clinical relevance remains uncertain. In a retrospective series, the small-bore Red43 distal aspiration catheter showed high target-vessel trackability and reperfusion rates without symptomatic intracranial hemorrhage, perforation, or dissection. For stent-retriever thrombectomy, the randomized DISTALS trial specifically evaluated the radially adjustable low-profile Tigertriever 13 and reported favorable technical efficacy and safety, though these device-specific angiographic findings should not be equated with established functional benefit. A complementary strategy is local pharmacological reperfusion. The RESCUE-TNK trial was designed to evaluate intra-arterial tenecteplase for primary or secondary medium-vessel occlusions considered unsuitable for mechanical clot retrieval. These developments support comparative evaluation of device- and drug-specific reperfusion strategies using clinical rather than purely angiographic endpoints, a shift that could fundamentally change how the field measures success.

Anatomical and clinical heterogeneity is equally central to the DMVO puzzle. In an endovascular-treated cohort of isolated posterior cerebral artery occlusions, van Landeghem and colleagues observed that P1 occlusions produced more severe and broader deficits, whereas P2 occlusions more often caused visual syndromes that may be underrepresented by the NIHSS. Deep infarction remained common despite angiographic reperfusion, a finding that challenges the assumption that successful recanalization always translates into tissue salvage. The case series by Xu and Yang illustrates the diagnostic complexity of bilateral paramedian thalamic infarction and the artery of Percheron, in which a unilateral fetal-type posterior cerebral artery may serve as an anatomical clue and treatment targeted upstream large-vessel pathology rather than the perforator itself. The Research Topic also examines markers of adverse outcome after reperfusion. A meta-analysis by Wu and colleagues associated early venous filling during thrombectomy with higher intracranial hemorrhage risk and lower functional independence, a potentially useful real-time warning sign that still requires standardized definition and prospective validation.

The next phase of DMVO research should move beyond a binary debate over whether distal thrombectomy is safe and effective. Future studies should identify treatment-responsive phenotypes by integrating disabling deficit, eloquent tissue involvement, occlusion segment, collateral and perfusion status, thrombus characteristics, procedural accessibility, and predicted device-related risk, while separating primary from secondary DMVO. Outcome measures should capture vision, language, cognition, fine motor function, and quality of life in addition to the modified Rankin Scale, the standard but admittedly blunt instrument for measuring stroke recovery. The neutral randomized trials appropriately challenge indiscriminate treatment, and together with the positive ORIENTAL-MeVO signal, they sharpen two essential questions: which carefully selected patients can achieve a meaningful net benefit from rapid complete reperfusion, and how future trials should be designed to identify the patients most likely to benefit from endovascular treatment. For now, the answer lies not in the catheter but in the convergence of advanced imaging, refined phenotyping, and a willingness to abandon the one-size-fits-all approach that has defined the field for too long.

Subject of Research: Endovascular treatment and patient selection in distal medium vessel occlusion stroke

Article Title: Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction

Article References: Broocks, G., Papanagiotou, P., Yeo, L. L. L., Gopinathan, A., Raz, E., & Meyer, L. (2026). Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction. Frontiers in Stroke, 5, Article 1967379. https://doi.org/10.3389/fstro.2026.1967379

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1967379

Keywords: stroke, mechanical thrombectomy, medium vessel occlusion, endovascular treatment, randomized trials, M2 occlusion, penumbral imaging, intracranial hemorrhage, reperfusion, patient selection, NIHSS, functional independence

The research team systematically searched three databases for comparative studies conducted in OECD countries, screening records in duplicate and extracting data with a standardised template. Methodological quality was assessed using relevant National Institutes of Health evaluation tools. The window of evidence stretched from 2013 to 2025, capturing more than a decade of experience with these units as they proliferated under various names and organisational models. In the end, twenty-eight studies met the inclusion criteria, forming the evidentiary backbone for an assessment of mortality, length of stay, hospital readmissions, ICU readmissions, costs, and adverse events in adult patient populations.

The first striking finding is how inconsistent the evidence is. Mortality patterns did not point in a single direction: some studies suggested potential benefits of intermediate care, others reported no clear differences, and still others highlighted potential risks for certain patients. According to the review, these discrepancies were often linked to differences in case-mix and admission criteria, meaning that who gets admitted to an intermediate care unit may matter as much as the unit itself. This is a familiar problem in health services research, where the intervention is not a drug with a fixed dose but a flexible organisational arrangement that varies from hospital to hospital and country to country.

Length of stay outcomes were similarly inconsistent. Some studies associated intermediate care units with shorter hospital stays, plausibly because enhanced monitoring allows earlier de-escalation from intensive care or faster recognition of deterioration on general wards. Others reported minimal or no improvement at all. The heterogeneity here mirrors the mortality findings and underscores a central methodological challenge: without standardised definitions of what constitutes an intermediate care unit, comparing results across studies becomes an exercise in approximation rather than precision. Units described under the same label may differ in nurse-to-patient ratios, physician coverage, available organ support, and the acuity of patients they accept.

Readmission outcomes offered somewhat more consistency, though not the kind advocates of these units might have hoped for. Rates of hospital readmission generally did not differ substantially between patients managed in intermediate care units and those treated in alternative levels of care. Advantages in reducing ICU readmissions, one of the theoretical selling points of step-down and step-up intermediate care, were uncommon across the reviewed literature. In other words, the evidence does not currently support the idea that routing patients through intermediate care reliably prevents them from bouncing back to intensive care or returning to hospital shortly after discharge.

Where the evidence does converge is on money. Cost savings were more consistently observed, with many studies indicating lower hospital expenditure when patients were managed in intermediate care units rather than in intensive care. The economic logic is straightforward: intensive care beds are among the most expensive resources in any hospital, dominated by high staffing ratios, continuous monitoring, and expensive technology. If clinically appropriate patients can be safely managed one step down, the marginal cost per patient falls. Yet the review adds an important caveat, noting that these savings were occasionally accompanied by unfavourable clinical trade-offs in specific patient groups, a reminder that financial efficiency and clinical safety do not automatically travel together.

Adverse event rates, by contrast, were generally comparable across settings. This is arguably reassuring: it suggests that, on balance, moving appropriately selected patients into intermediate care does not systematically expose them to more harm than keeping them in intensive care or on general wards. But comparability is a modest benchmark. The review’s overall verdict is that effects on mortality and length of stay remain inconclusive, largely because of methodological and organisational heterogeneity across the evidence base, while the case for cost savings is the most consistent signal in the literature.

The pattern that emerges is one of selective benefit. Intermediate care units appear most useful for moderate-risk populations, patients too unstable for a general ward but not sick enough to require full intensive care. For these patients, enhanced monitoring at lower staffing intensity represents a rational middle ground. For high-risk patients, however, the suitability of intermediate care is uncertain, and the review suggests that admitting the wrong patients into these units could carry risks. Patient selection, in other words, is not a bureaucratic detail but the decisive variable that determines whether an intermediate care unit helps, does nothing, or harms.

For hospital planners and policymakers, the implications are significant. Many health systems face simultaneous pressures of ageing populations, rising critical care demand, and constrained budgets. Intermediate care units have been promoted as a way to relieve ICU congestion, improve patient flow, and reduce costs simultaneously. The new review partially vindicates that promise on the economic front while cautioning against overclaiming clinical benefits that the current evidence cannot support. It also highlights the danger of treating these units as a one-size-fits-all solution, since their effects appear to depend heavily on local case-mix, admission protocols, and the specific clinical purpose each unit is designed to serve.

The authors argue that standardised definitions, clearer admission criteria, and improved reporting are essential to strengthen future evidence. Until the field agrees on what an intermediate care unit actually is, comparative research will continue to produce the kind of mixed results this review documents. In the meantime, the practical takeaway for clinicians and administrators is a measured one: intermediate care units are a promising and generally cost-saving component of hospital architecture, best deployed for selected moderate-risk patients, and their expansion should be guided by explicit criteria rather than enthusiasm. As these units continue to spread across OECD health systems, the review provides both a warning against uncritical adoption and a roadmap for the research needed to settle the remaining questions.

Subject of Research: Effects of intermediate care units on patient outcomes and hospital resource use in OECD countries

Article Title: The effect of intermediate care units on patient and hospital utilisation outcomes: a systematic literature review

Article References: Detollenaere, J., Van de Voorde, C., Castanares-Zapatero, D., Bouckaert, N., Lefèvre, M., & Van den Heede, K. (2026). The effect of intermediate care units on patient and hospital utilisation outcomes: a systematic literature review. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15737-y

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15737-y

Keywords: intermediate care units, intensive care, systematic review, patient outcomes, hospital costs, length of stay, readmissions, mortality, health services research, patient selection, OECD countries, critical care

The technology at the heart of this effort, chimeric antigen receptor T-cell therapy, involves extracting a patient’s own T lymphocytes and genetically engineering them to express an artificial receptor that recognises a specific molecular target. In oncology, the most common target is CD19, a protein displayed by many B-cell malignancies, but the same target has proved decisive in autoimmunity for a different reason: pathogenic B cells drive diseases such as systemic lupus erythematosus, myositis and systemic sclerosis. When engineered CAR T cells encounter CD19-expressing B cells, they eliminate them with a depth that conventional immunosuppressive drugs rarely achieve, and in doing so they can interrupt the autoimmune cascade at its source. Early clinical reports have described patients with severe, treatment-refractory disease entering drug-free remission after a single infusion, an outcome that would have seemed implausible only a few years ago.

Yet the expert panel is emphatic that enthusiasm must be tempered by caution. CAR T-cell therapy remains an evolving discipline in autoimmunity, with most evidence derived from small, single-arm studies rather than large randomised trials. Because high-level evidence is still emerging, the recommendations were constructed using the EBMT’s structured practice harmonisation methodology, a formal consensus process designed precisely for situations where clinical practice is racing ahead of definitive data. The result is not a rigid protocol but a shared framework: a set of expectations about who should be treated, where, by whom, and with what degree of monitoring before and after the cells are infused.

The cornerstone of the framework is patient selection. The consensus recommends considering CAR T-cell therapy only for patients with severe autoimmune disease that remains active or progressive despite appropriate standard treatment, meaning that conventional therapies must have been given a genuine opportunity to work before the cellular option is pursued. Whenever possible, the experts say, treatment should be delivered within the controlled environment of a clinical trial, where systematic data collection can accelerate the field’s understanding of efficacy and risk. When trial participation is not feasible, the decision to proceed should be documented through a multidisciplinary assessment involving both autoimmune disease specialists and haematology or cellular therapy experts, ensuring that perspectives from both sides of this unusual therapeutic border are represented before an irreversible step is taken.

Where the therapy is delivered matters as much as who receives it. The recommendations call for treatment in experienced centres, preferably those accredited by FACT or JACIE for immune effector cell therapies, because accreditation signals consistent quality and safety standards in cell processing, manufacturing oversight and toxicity management. The panel also stresses that autoimmune diseases differ enormously from one another in organ involvement, comorbidity burden and prior treatment exposure, so disease-specific assessment and monitoring remain essential even within a common framework. A patient with refractory lupus nephritis, a patient with severe multiple sclerosis and a child with juvenile dermatomyositis present distinct anatomical and immunological challenges, and the guidance explicitly resists the temptation to impose a one-size-fits-all pathway on this heterogeneity.

Raffaella Greco of San Raffaele Hospital in Milan and Dominique Farge of St-Louis Hospital in Paris, who coordinated the consensus process, framed the initiative as a balance between promise and prudence. CAR T-cell therapy, they noted, is emerging as an important new therapeutic approach for patients with severe and refractory autoimmune diseases, but the field is evolving rapidly, and careful patient selection, multidisciplinary management and long-term follow-up are essential. Their stated aim is a shared framework that supports patient safety and greater consistency in clinical practice while the evidence base continues to be built, a formulation that captures the panel’s central tension: how to standardise care without freezing a science that is still moving.

A substantial portion of the guidance concerns what happens around the infusion itself. The recommendations place strong emphasis on activities before and after CAR T-cell administration, including diagnostic assessment, treatment planning, immune monitoring and the management of treatment-related toxicities. One of the most clinically demanding challenges highlighted is the need to distinguish inflammatory complications caused by the therapy, such as cytokine release syndrome or immune effector cell-associated neurotoxicity, from a flare or progression of the underlying autoimmune disease. These entities can overlap in presentation, and misattributing one for the other can lead to harmful treatment decisions. The panel therefore calls for close collaboration between haematology, cellular therapy and autoimmune disease teams, so that the interpretation of fevers, neurological changes or serological shifts is informed by expertise on both sides.

Long-term follow-up and systematic data collection emerge as the panel’s most urgent priorities. The experts strongly recommend reporting every patient treated with CAR T-cell therapies to the EBMT Registry, a step intended to build understanding of long-term outcomes, durability of response and late toxicities. This emphasis echoes recent statements from both the United States Food and Drug Administration and the European Medicines Agency, which have underscored the need for extended surveillance of patients receiving these genetically modified cells. Because CAR T cells can persist in the body for years and deplete B-cell lineages for prolonged periods, questions about hypogammaglobulinaemia, infection risk, secondary malignancy and immune reconstitution cannot be answered without registry-scale data. The EBMT Registry has accordingly been expanded to support structured follow-up of patients with autoimmune diseases across participating centres, converting scattered clinical anecdotes into a coherent evidence base.

Children and adolescents receive dedicated attention in the update, reflecting both the particular vulnerability of younger patients and the relative scarcity of paediatric evidence. The recommendations call for multidisciplinary assessment that weighs disease severity and previous treatments against factors unique to growing patients: organ damage accumulated during development, fertility preservation, quality of life and the long-term consequences of chronic immunosuppression, which in young patients can span decades. The calculus of offering a single potentially curative infusion to a teenager instead of a lifetime of steroid and immunosuppressant exposure is compelling, but the panel insists that the limited paediatric data demand heightened deliberation rather than reduced scrutiny.

Looking forward, the authors identify priorities that will shape the next phase of research: larger controlled clinical trials to establish efficacy beyond single-arm cohorts, biomarkers capable of predicting which patients will respond and which will suffer toxicity, novel CAR targets that might extend the approach beyond B-cell-driven disease, and strategies to improve treatment access so that the therapy does not remain confined to a handful of specialised centres. The 2026 recommendations are explicitly conceived as living guidance under the auspices of EBMT, ISCT and JACIE, and they will continue to evolve as new evidence and clinical experience emerge. For now, they represent the most comprehensive attempt yet to impose scientific discipline on one of the most exciting developments in modern immunology, ensuring that as CAR T cells march from the oncology ward into the rheumatology clinic, they do so under conditions designed to protect the very patients they are meant to help.

Subject of Research: Consensus recommendations for CAR T-cell therapy in severe autoimmune diseases

Article Title: International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases

Article References: International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR T-cell therapy, autoimmune diseases, EBMT, ISCT, JACIE, The Lancet Rheumatology, patient selection, immune monitoring, long-term follow-up, clinical trials, paediatric care, registry data

The research, published in BMC Health Services Research, examined Prehospital Assessment Units, or PAUs, which are paramedic-staffed units designed to strengthen acute care pathways by assessing patients before a decision is made about hospital conveyance. The model sits squarely within a broader international trend toward non-conveyance, in which emergency medical services are asked not merely to transport patients but to evaluate them at the scene, treat what can be treated, and connect people with the right level of care, which is sometimes no hospital visit at all. Sustainable implementation of such services, the Danish team argued, depends on cooperation across sectors that have historically operated in separate silos.

To capture how the model is landing on the ground, the researchers used a convergent parallel mixed-methods design, running quantitative questionnaires and qualitative focus groups simultaneously and then integrating the results. Data were collected between April and August 2024 across the emergency medical services, hospital emergency departments, general practice, and municipal acute care in the Region of Southern Denmark. The questionnaire drew on previously published and validated outcome measures, while the qualitative material was analysed using Reflexive Thematic Analysis, a technique in which researchers systematically code narratives and construct themes that interpret shared experiences rather than simply counting them.

The numbers tell a strikingly positive story. Of 231 healthcare professionals who responded to the questionnaire, a response rate of 51.7 percent, 166 were included after prespecified exclusions. On a one-to-five scale, the median score for the Acceptability of Intervention Measure was a perfect 5.00, with an interquartile range of 4.00 to 5.00, meaning that at least three quarters of respondents rated acceptability at four or above. The Intervention Appropriateness Measure yielded a median of 4.13, and the Feasibility of Intervention Measure a median of 4.25, with interquartile ranges of 4.00 to 5.00 and 3.75 to 5.00 respectively. In plain terms, the clinicians who interact with PAUs overwhelmingly regard them as acceptable, largely appropriate, and broadly workable.

Numbers alone, however, cannot explain why a service succeeds or stalls, and this is where the qualitative arm of the study earns its keep. Three focus groups involving 18 participants drawn from across the acute care spectrum captured cross-sector experiences in depth. The thematic analysis generated three themes: the contested work of patient selection, integration in acute care, and building understanding through shared narratives. Together, these themes map the social and organisational terrain on which the PAU model either flourishes or frays, revealing that a service can be well liked in principle while still generating friction at its operational edges.

The first theme, patient selection, points to what may be the model’s most consequential challenge. Deciding which patients can be safely assessed and left at home, and which genuinely need an emergency department, is inherently contested work, and the qualitative accounts suggest that boundaries around this decision are not always clear. When frontline staff in different parts of the system disagree about who belongs in a PAU’s remit, consistency suffers, and the researchers identified this variability as a negative implementation determinant, a factor that may hinder uniform delivery of the service across settings and shifts.

The second theme, integration in acute care, extends that concern to the institutional level. A prehospital assessment unit does not operate in a vacuum; its value depends on how smoothly it slots into emergency departments, general practice, and municipal acute care. The study found evidence of role negotiation, with professionals working out where PAU staff fit within established hierarchies and workflows. Accounts of this negotiation, alongside variability in feasibility scores, revealed further negative determinants rooted in contextual factors and unclear boundaries between services. These are not failures of the model so much as growing pains of a system learning to share responsibility for acutely ill patients across traditional dividing lines.

The third theme, however, offers a genuine cause for optimism. Shared narratives, the stories professionals tell each other about the service, emerged as a powerful engine of understanding. Qualitative narratives reinforced the quantitative findings, legitimising the PAUs and highlighting their contribution across sectors. When emergency department physicians, general practitioners, municipal staff, and paramedics exchange experiences of the unit in action, abstract scepticism gives way to concrete appreciation of what the service can and cannot do. The researchers identified this cross-sector contribution and the role of shared experience as positive implementation determinants, suggesting that communication itself is an intervention worth investing in.

The methodological machinery behind these conclusions deserves attention. By using a joint display to align quantitative ratings with qualitative determinants, the researchers could check whether the numbers and the narratives told the same story, and largely they did. The high acceptability scores were corroborated by qualitative accounts that legitimised the service, while the spread in feasibility scores was echoed by focus group discussions of selection disputes and integration struggles. This convergence strengthens confidence that the findings reflect real professional experience rather than artefacts of either surveys or interviews. The study was classified as a quality assurance initiative under Danish legislation, exempt from formal ethical review, with informed consent obtained from all participants and data handling compliant with the General Data Protection Regulation.

For health systems everywhere grappling with emergency department overcrowding and ageing populations, the Danish experience carries a clear message. Paramedic-staffed prehospital assessment units can earn the trust of the clinicians around them, and that trust is measurable, with median acceptability scores at the top of the scale. But acceptance is only the first hurdle. The contested work of deciding who can be safely left at home, and the institutional work of weaving a new service into the fabric of acute care, will determine whether such models deliver consistent benefits or uneven ones. The authors conclude that healthcare professionals reported predominantly positive experiences of the PAU model, while the challenges they identified reflect contextual factors and unclear boundaries that may hinder consistent implementation. In other words, the idea has won the argument; now comes the harder task of winning the workflow.

Subject of Research: Implementation of paramedic-staffed prehospital assessment units in acute care

Article Title: Healthcare professionals’ experiences of implementing paramedic-staffed prehospital assessment units in acute care: a mixed-methods study

Article References: Rasmussen, H. M., Løkke, A., Biesenbach, P., Lassen, A., Christensen, A. F., Hoffmann, E., Mikkelsen, S., & Elkjaer, M. (2026). Healthcare professionals’ experiences of implementing paramedic-staffed prehospital assessment units in acute care: a mixed-methods study. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15764-9

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15764-9

Keywords: prehospital care, paramedics, non-conveyance, emergency medical services, acute care, implementation science, mixed methods, acceptability, feasibility, patient selection, health services research, Denmark

The technology behind ECPR is borrowed from extracorporeal membrane oxygenation, or ECMO, the machine that made headlines during the COVID-19 pandemic as a last-resort lung support. In venoarterial ECMO, blood is drained from large veins, passed through a membrane oxygenator that adds oxygen and removes carbon dioxide, and pumped back into the arterial system. Applied during cardiac arrest, this circuit can push roughly 2.0 liters per minute through the body—more than three times what compressions achieve—sustaining the brain, heart, and other organs while clinicians treat the underlying cause of the arrest. The catch is time. Studies reviewed by the authors show that for every ten-minute delay between collapse and the start of ECPR, the likelihood of favorable neurological recovery falls significantly, which is precisely why researchers have begun moving the machines out of the hospital and into ambulances.

The randomized trial evidence is striking but nuanced. In the American ARREST trial, patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation who received early ECPR were discharged from the hospital at a rate of 43 percent, compared with just 7 percent among those receiving conventional resuscitation. Yet two European trials, INCEPTION in the Netherlands and PRAGUE-OHCA in the Czech Republic, found no such advantage—and the review’s authors point to a telling detail: in those studies, the average time to ECPR initiation stretched to roughly 61 to 74 minutes. The emerging consensus is that ECPR delivers meaningful benefit only when the so-called low-flow duration, the interval without effective circulation, stays under about 60 minutes, and only in carefully selected patients. Even then, the sub-60-minute mark is a benchmark rather than an absolute cutoff, since good outcomes have occasionally been achieved beyond it when compressions remain high quality.

Prehospital ECPR aims to attack the clock directly. Instead of resuscitating at the scene and then transporting, specialized teams reach the patient quickly and establish ECMO support either on-site or inside a mobile intensive care unit, working in parallel with compressions and airway management. Observational data suggest the approach is feasible: favorable neurological outcomes have been reported in roughly 20 to 25 percent of prehospital ECPR patients. A French analysis by Leroux and colleagues found no survival difference between prehospital and in-hospital initiation, but the low-flow duration was a full 30 minutes shorter when ECMO was started in the field. In Germany, Walter and colleagues achieved survival with good neurological function in 24.6 percent of 69 prehospital ECPR patients, while a French helicopter-borne team described by Hutin and colleagues still recorded 15 percent favorable survival despite low-flow times exceeding 110 minutes.

A handful of systems worldwide have made this a reality. Paris pioneered mobile ECPR in 2011, dispatching 24/7 teams—an anesthesiologist or emergency physician, an anesthesia nurse, and a paramedic—alongside standard mobile intensive care units, with a goal of establishing ECMO within 60 minutes of collapse. The first reported Paris case involved a marathon runner who received 4.5 liters per minute of extracorporeal flow about an hour after the emergency call and began recovering organ function within two days. In Albuquerque, New Mexico, the University of New Mexico partnered with the local fire department in 2019 to field a specially equipped ambulance crewed by an ECPR-trained intensivist and two paramedics, targeting witnessed arrests where hospital transport would exceed 35 minutes. The Netherlands equips all of its air ambulance units with ECPR capability, and in Regensburg, Germany, ambulance crews and the ECPR team are dispatched simultaneously, with exclusion criteria such as trauma, terminal illness, and unwitnessed arrest filtering candidates before cannulation begins.

The procedure itself relies on peripheral cannulation rather than open-chest surgery. Central access, which requires a sternotomy and placement of catheters in the right atrium and aorta, is considered infeasible in the field. Instead, teams use the percutaneous Seldinger or semi-Seldinger technique, typically accessing the femoral artery and vein, sometimes with ultrasound guidance. Recent studies support both approaches in prehospital protocols, and the review’s authors argue that restricting field programs to these percutaneous methods shortens intervention time and reduces complications. The technique is not without hazards: femoral cannulation carries a real risk of distal limb ischemia, particularly when a distal perfusion catheter cannot be placed, and achieving hemostasis in anticoagulated patients is difficult in uncontrolled environments. Maintaining aseptic technique at a roadside scene presents yet another challenge that early enthusiasm sometimes understates.

Training is the other formidable barrier. International teams typically comprise at least one physician, a nurse, a paramedic, and intensive care expertise, all credentialed in ECMO circuit setup, management, and troubleshooting. An Australian program described in the review trained 11 physicians and 6 critical care paramedics with no prior ECMO experience through a multiphase curriculum combining animal models, cadaver-based cannulation practice, simulation scenarios, and formal examinations; every participant ultimately met the learning objectives. The Extracorporeal Life Support Organization recommends certified basic and advanced ECMO training for anyone involved in ECPR. Patient selection is equally strict: candidates generally must have a witnessed arrest, immediate bystander CPR, a shockable initial rhythm such as ventricular fibrillation, and a low-flow duration under 60 minutes, while terminal illness, traumatic arrest, and advanced age—often capped at 65 to 70 years in French and Dutch protocols—exclude patients. Even so, only an estimated 2 to 10 percent of out-of-hospital cardiac arrest patients are potential candidates.

For Turkey, the review paints a sobering baseline. The national TROHCA study of 1,003 out-of-hospital arrests found that only 4.4 percent of patients reaching the hospital survived to discharge and just 2.7 percent achieved favorable neurological outcomes—figures below the global average, driven in part by bystander CPR rates of only about 2 to 5 percent. Turkish ECMO experience is limited to in-hospital cases: a Koşuyolu hospital series reported 36.4 percent neurologically intact survival among 22 in-hospital arrest patients, a Başkent University series weaned only 30.4 percent of 46 cardiac patients from VA-ECMO, and only a small number of Turkish centers are registered with ELSO. No prehospital ECPR case has ever been reported in the country, and no formal ECMO transport teams exist. The authors propose a phased pilot built on a centralized hub-and-spoke model with a Targeted-Dispatch strategy: local 112 teams begin high-quality resuscitation immediately, and if a witnessed arrest meets strict criteria without return of spontaneous circulation within ten minutes of advanced life support, a dedicated ECPR team deploys from a hub hospital to perform ultrasound-guided percutaneous cannulation in the field or a mobile intensive care unit.

Cost looms over any such plan. An Australian analysis by Zmudzki and colleagues estimated the average prehospital ECPR cost per patient at 12,741 Australian dollars, with a cost-effectiveness ratio near 44,000 dollars per quality-adjusted life year—falling to roughly 22,000 dollars when secondary benefits such as increased organ donation were included. The review’s authors stress that ECPR should be framed not as a replacement for basic life support but as an apex intervention layered on top of a strengthened chain of survival, and they call for ethical and legal governance covering clinical liability, consent, and withdrawal criteria, alongside formal cost-utility analysis before any rollout. Their proposed framework, they caution, is an expert-informed pilot concept rather than a validated protocol, limited initially to metropolitan regions with short transport distances and ECPR-capable referral hospitals. If prospective studies confirm feasibility, the idea of a heart-lung machine humming beside a roadside could move from medical science fiction to standard emergency care—one carefully selected patient at a time.

Subject of Research: Prehospital extracorporeal cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest

Article Title: Prehospital extracorporeal cardiopulmonary resuscitation: global trends and the Turkish perspective

Article References: Denizli, F., Kınış, Z., & Hızaler, E. (2026). Prehospital extracorporeal cardiopulmonary resuscitation: global trends and the Turkish perspective. Journal of Emergency and Disaster Medicine, 2(1), Article 20. https://doi.org/10.1007/s44467-026-00023-y

Image Credits: AI Generated

DOI: 10.1007/s44467-026-00023-y

Keywords: ECPR, ECMO, cardiac arrest, prehospital care, resuscitation, out-of-hospital cardiac arrest, emergency medicine, patient selection, cannulation, cost-effectiveness, Turkey, emergency medical services

The review, led by Yuxiang Li and Zhigang Mei of Hunan University of Chinese Medicine together with colleagues, takes stock of why endovascular therapy (EVT), which has revolutionized treatment of large vessel occlusion, still leaves a substantial proportion of patients disabled. The authors identify four interlocking challenges: the narrow therapeutic time window during which treatment must begin, suboptimal patient selection, difficulty achieving a first-pass effect in which the clot is removed on the initial attempt, and futile reperfusion—the situation in which blood flow is restored to tissue that can no longer benefit from it.

Futile reperfusion is the review’s central villain, and it wears several faces. The no-reflow phenomenon prevents blood from penetrating the downstream microvasculature even after the main artery is cleared. Reocclusion can shut the vessel again. Ischemia-reperfusion injury means that the very act of restoring blood flow unleashes a cascade of reactive oxygen species, inflammatory signaling, and damage-associated molecular patterns that injure the tissue they were meant to save. On top of these come hemorrhagic transformation, in which the damaged blood-brain barrier gives way to bleeding into the infarcted tissue, and malignant cerebral edema, the catastrophic swelling that can compress the brain fatally within days.

To combat these failures, the authors begin with diagnosis. Multimodal neuroimaging—combining non-contrast CT, diffusion-weighted imaging, CT or MR angiography, perfusion imaging, and collateral status assessment—now allows clinicians to distinguish patients whose brain tissue is salvageable from those in whom intervention would be futile. The review highlights how predictive biomarkers and artificial intelligence are being layered onto these imaging modalities to refine prognostic prediction and sharpen patient selection criteria. Machine learning models trained on large imaging datasets can, in principle, quantify the ischemic core, estimate penumbral salvage tissue, and predict the likelihood of functional independence on the modified Rankin Scale with a speed and consistency that human readers cannot match in the middle of the night.

The second pillar of the proposed strategy is cerebral cytoprotection, a concept that has had a checkered history in stroke research but is now being reinvigorated by mechanistic insights. Rather than attempting to rescue neurons with a single magic bullet, the emerging generation of cytoprotective strategies aims to stabilize brain energy metabolism across the entire neurovascular unit. The review describes interventions that shore up mitochondrial function, the cellular power plants whose failure during ischemia triggers programmed cell death; that preserve the endothelial glycocalyx, the delicate sugar-rich layer lining brain microvessels that prevents leukocytes and platelets from clogging capillaries; and that protect pericytes, the contractile cells wrapped around capillaries whose death contributes to the no-reflow phenomenon.

Notably, the authors argue that effective cytoprotection could do more than reduce injury—it could extend the therapeutic time window itself. If brain cells can be kept metabolically viable for longer while the artery remains blocked, the hard six-hour boundaries that currently govern treatment decisions might become more flexible, allowing patients who arrive late to hospitals to still benefit from mechanical thrombectomy. The review also points to preclinical evidence supporting the targeting of the glymphatic system, the brain’s waste-clearance network driven by cerebrospinal fluid flow through perivascular channels, which depends heavily on aquaporin-4 channels and may influence edema resolution and reperfusion recovery.

The third pillar concerns the endovascular procedure itself. The review surveys device innovations in stent retrievers and aspiration catheters designed to improve the first-pass effect, since each additional pass of a device through the vessel increases the risk of endothelial damage, distal embolization, and vasospasm. It also examines optimized bridging thrombolysis strategies, weighing intravenous thrombolysis with tissue-type plasminogen activator against the newer agent tenecteplase, which offers greater fibrin specificity and easier administration. Tailored adjuvant antithrombotic regimens—balancing the prevention of reocclusion against the risk of hemorrhagic transformation—round out the peri-procedural toolkit, with particular attention to patients with intracranial atherosclerotic stenosis, in whom standard approaches often fall short.

Underlying all of this is a sobering assessment of why so many promising therapies have failed to translate from bench to bedside. The review is candid that preclinical models, particularly the middle cerebral artery occlusion model in rodents, are oversimplified relative to the heterogeneous, comorbidity-laden human stroke population. Young, healthy laboratory animals with standardized infarcts respond to cytoprotective agents in ways that elderly diabetic patients with hypertension, atrial fibrillation, and atherosclerotic disease simply do not. The absence of patient stratification for tailored cytoprotection is identified as a critical gap: a therapy that stabilizes mitochondria may help one subgroup while doing nothing—or harm—for another, and without precision biomarkers to identify who should receive what, trials are doomed to average out to null results.

The authors also emphasize the systemic dimension of peri-procedural care. Blood pressure management, collateral circulation support, remote ischemic conditioning, and even neuromodulation approaches such as cathodal transcranial direct current stimulation appear in the synthesis as adjuncts that may influence outcomes. The unifying theme is that stroke treatment does not end when the clot is extracted; the hours surrounding the procedure, from prehospital triage through intensive care monitoring, constitute a continuous therapeutic opportunity that current practice fragments into disconnected episodes.

What emerges from the review is a vision of stroke medicine in which successful recanalization is treated as a necessary but insufficient condition for recovery. In this vision, artificial intelligence-assisted imaging selects the right patient at the right time, cytoprotective regimens keep the endangered brain metabolically alive while the interventionalist works, refined devices clear the vessel in a single pass, and microvascular- and glymphatic-targeted therapies ensure that restored blood flow actually nourishes tissue rather than igniting inflammation. The authors are careful to frame these as directions warranting further investigation rather than established practice, and they call for optimized preclinical models and precision biomarkers to close the translation gap. But their core message is clear: the era of celebrating recanalization alone is ending, and the next chapter of acute ischemic stroke treatment will be written in the integration of technologies that protect the brain as vigorously as they unblock it.

Subject of Research: Integrated neuroimaging, cytoprotection, and endovascular strategies for improving outcomes in acute ischemic stroke

Article Title: Beyond recanalization: integrating neuroimaging, cytoprotection and endovascular strategies in acute ischemic stroke

Article References: Li, Y., Sun, F., Zhao, L., Wu, B., Xiong, H., Zhou, Y., Zhang, W., & Mei, Z. (2026). Beyond recanalization: integrating neuroimaging, cytoprotection and endovascular strategies in acute ischemic stroke. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08981-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08981-7

Keywords: acute ischemic stroke, endovascular therapy, futile reperfusion, cerebral cytoprotection, neuroimaging, artificial intelligence, mechanical thrombectomy, no-reflow phenomenon, reperfusion injury, glymphatic system, large vessel occlusion, patient selection

The research, led by Xiaoying Zhu of Nanjing University of Chinese Medicine and the Nossal Institute for Global Health at the University of Melbourne, together with colleagues including Daniel Ll Strachan, Shenglan Tang, Tiara Marthias, Ajay Mahal and Barbara McPake, is built on face-to-face, semi-structured interviews with 21 physicians sampled from two hospitals with deliberately different incentive structures. Conducted in 2024, the interviews probed how doctors experience and respond to the Diagnosis-Related Group reform, known globally as DRG payment. The analysis followed an inductive thematic approach before applying a deductive framework, allowing the researchers to surface patterns in the physicians’ own words before testing them against established behavioural theory. The result is one of the most granular portraits to date of what health economists call cream-skimming: the systematic selection of profitable patients and the subtle exclusion of those whose care is expected to cost more than the hospital will be paid.

DRG payment systems, first developed in the United States and now deployed in dozens of countries, were designed to curb the runaway costs of fee-for-service medicine. Instead of paying hospitals for every test, drug and bed-day, the payer assigns each admission to a fixed-price category based on the diagnosis, so the hospital receives a predetermined sum regardless of how much the treatment actually costs. In theory, this pushes hospitals to become more efficient, eliminate unnecessary procedures and shorten stays. But the same mechanism creates a structural hazard: a patient whose actual treatment exceeds the fixed price becomes a financial loss, and a patient who needs less than the fixed price generates a surplus. In China, where the government has simultaneously pledged to advance healthcare equity while rolling out DRG reform nationwide, the tension between fiscal discipline and fair access has never been sharper.

The Nanjing interviews reveal that the phrase ‘more work means less pay’ is not a complaint muttered in passing but an operating principle that shapes admission decisions. Physicians described assessing, often within minutes, whether the expected DRG reimbursement would cover the anticipated treatment costs of a particular patient. Clinically complex cases — those with multiple comorbidities, unclear diagnoses, or likely prolonged stays — emerged as the paradigmatic financially risky admissions. The study found that patient selection was not framed by the doctors as greed or malice, but as an adaptive response: a rational adjustment to incentives that penalize exactly the kind of resource-intensive care that clinical complexity demands. When the payment rule makes complexity costly, the doctors’ calculus bends toward avoidance, whether they want it to or not.

What distinguishes this study is its effort to dissect the anatomy of the decision rather than merely cataloguing its existence. The researchers found that physicians’ choices were shaped by three interacting dimensions: capability, opportunity and motivation. Capability captured the physician’s confidence in managing financially risky cases under the constraints of the fixed payment — a doctor experienced in the relevant specialty, or familiar with the DRG category’s payment boundary, may feel able to admit a patient whose costs would overshoot the reimbursement. Opportunity encompassed the physical and social conditions that allowed a physician to balance financial risk against quality of care, including the availability of referral channels, the support of the hospital environment, and the flexibility to structure a treatment plan that keeps costs within the payment envelope. Motivation concerned the value physicians placed on different possible outcomes — the welfare of the patient, the fulfilment of professional obligations, and the recognition their decisions would earn within the hospital’s performance system.

The alignment of these three dimensions proved decisive. Physicians were most likely to admit a financially risky patient when all three conditions held simultaneously: when they believed the patient could be effectively managed under DRG payment, when they expected their decision to produce meaningful and recognised outcomes, and when they valued those outcomes, including the patient’s welfare and their own sense of professional duty. Remove any one of the three — sap a doctor’s confidence that the case can be managed without a punishing loss, block the pathways that would make careful management possible, or hollow out the recognition and reward for doing the right thing — and the willingness to accept a costly patient collapses. This finding reframes cream-skimming not as a fixed character flaw of physicians but as a system-dependent behaviour, sensitive to how hospitals structure support, performance metrics and clinical pathways.

The implications reach far beyond Nanjing. DRG reform is among the most ambitious payment experiments in modern health policy, and China’s version is being implemented at a scale no other health system has attempted, covering thousands of hospitals and hundreds of millions of insured patients. Studies from European and East Asian systems have repeatedly documented the same perverse incentives — upcoding of diagnoses to reach higher-paying categories, premature discharges, and the quiet diversion of complex patients to other institutions. But the Nanjing study adds a crucial layer of mechanism, showing how the behaviour is mediated by doctors’ perceptions of financial risk and by the institutional scaffolding that either absorbs or amplifies that risk. Whether a high-cost patient is admitted may depend less on the payment rule itself than on whether the hospital has created the conditions under which a physician can manage the case without absorbing the loss personally or as a department.

The authors’ conclusions point toward a set of concrete correctives. Improving equitable access, they argue, requires realigning hospital performance metrics with clinical need rather than purely with financial outcomes, so that physicians who take on difficult patients are recognised and rewarded rather than penalized. It requires strengthening referral and post-acute care pathways, so that complex cases can move through the system in ways that distribute cost and responsibility rather than concentrating both on a single admission. And it requires reducing reliance on individual risk-based decision-making through team-based support, spreading the burden of financially risky cases across the institution instead of leaving each physician to weigh it alone at the bedside. In each case, the goal is the same: to change the ecology in which the admission decision is made, rather than to exhort doctors to behave better within an ecology that punishes them for it.

For patients, the stakes are stark. A physician who declines or deflects a complex admission does not simply shift an accounting problem; the patient may face longer waits, fragmented care, or repeated referrals before reaching someone willing to treat them. For the most vulnerable — the elderly with multiple chronic conditions, the poor with advanced disease — the cumulative effect of thousands of individual admission decisions, each nudged by the same financial logic, is a system that quietly rationed care by complexity. That is the opposite of what health equity requires, and it is why the study’s authors frame their work as an urgent input into China’s equity commitments. The research received no specific grant from any funding agency; Zhu’s PhD program was supported by a China Scholarship Council–University of Melbourne PhD Scholarship.

The study is a reminder that health payment reform is never merely a technical exercise in accounting. Every fixed price, every performance indicator, every cost-allocation rule lands eventually on a human decision made under pressure — and when the rule says that the hardest patients are the least rewarding, the system must decide whether it intends that outcome or will redesign itself to prevent it. The Nanjing physicians interviewed for this study did not invent the dilemma; they inherited it from the architecture of the reform. What the study makes clear is that the architecture can be changed, and that the willingness of doctors to care for those who need them most depends on it. As China refines its DRG rollout, the words of its own clinicians — more work means less pay — stand as both a warning and a blueprint for reform.

Subject of Research: Physicians' patient selection decision-making under China's DRG hospital payment reform in Nanjing

Article Title: “More work means less pay”: a qualitative understanding of physicians’ patient selection decision-making under DRG reform in Nanjing, China

Article References: Zhu, X., Strachan, D. L., Tang, S., Marthias, T., Mahal, A., & McPake, B. (2026). “More work means less pay”: a qualitative understanding of physicians’ patient selection decision-making under DRG reform in Nanjing, China. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03044-1

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03044-1

Keywords: DRG payment, cream skimming, patient selection, physician behaviour, health policy, health equity, China, Nanjing, financial incentives, hospital payment reform, qualitative research, health insurance

The research team, led by Knut Liepe of the Department of Nuclear Medicine at GH Hospital Klinikum Frankfurt (Oder) in Germany, together with colleagues from Ruhr University Bochum’s Johannes Wesling Hospital Minden and independent collaborators, examined 91 patients who underwent primary staging with [99mTc]Tc-PSMA SPECT/CT. Each patient received a median administered activity of 670 megabecquerels of the radiotracer [99mTc]Tc-MIP-1404, with a range of 470 to 792 megabecquerels. The imaging technique fuses single-photon emission computed tomography, which maps the distribution of the radiolabelled prostate-specific membrane antigen ligand, with computed tomography, which provides anatomical context. Together, the two modalities allow physicians to visualise both the primary tumour within the prostate and any metastatic deposits in pelvic lymph nodes or distant organs.

PSMA—prostate-specific membrane antigen—is a transmembrane protein expressed abundantly and relatively homogeneously on the surface of prostate cancer cells, a biological property that has made it one of the most successful molecular imaging targets in oncology. Radiolabelled ligands such as MIP-1404 bind to PSMA, concentrating radiation signal at tumour sites and enabling detection of lesions that conventional bone scans and CT frequently miss. While PSMA PET/CT has become the reference standard for staging in high-income centres, guided by landmark randomised trials such as proPSMA, PET infrastructure is expensive, dependent on short-lived isotopes, and unevenly distributed globally. SPECT cameras, by contrast, are far more widespread, which is precisely why the German team’s analysis of when technetium-based PSMA SPECT/CT delivers meaningful diagnostic yield matters so much.

The core of the study is a statistical interrogation of how two pre-imaging variables interact to determine what the scan will find. Using univariate and multivariate nominal logistic regression, the investigators tested whether the initial PSA level (iPSA) and the International Society of Urological Pathology grade group—assigned from 1, the least aggressive, to 5, the most aggressive—predicted the presence of metastatic disease. Both emerged as independent predictors. The effect of PSA was the stronger of the two, with a p-value of 0.0004, while ISUP grade remained significant at p equal to 0.0015. In practical terms, a man’s blood test and his biopsy pathology, taken together, already encode much of the information the scanner will later confirm.

The detection-rate thresholds that emerged from the analysis are strikingly concrete. Detection rates of metastatic disease on [99mTc]Tc-PSMA SPECT/CT exceeded 50 percent in two patient subgroups: those with ISUP grades 1 to 3 whose initial PSA exceeded 50 nanograms per millilitre, and those with ISUP grades 4 to 5 whose initial PSA exceeded 20 nanograms per millilitre. Even more dramatically, metastases were detected in every single patient whose initial PSA was above 50 nanograms per millilitre, regardless of how indolent or aggressive the tumour appeared under the microscope. For clinicians weighing whether to order the scan, these cutoffs offer an evidence-based filter: below them, the probability of finding spread disease drops enough that the examination may not justify its cost and radiation exposure.

Beyond the headline thresholds, the study revealed that the two risk variables shape not just whether metastases appear but where they appear. Among patients with ISUP grades 1 to 3 across all PSA levels, and among those with ISUP grades 4 to 5 whose PSA was 20 nanograms per millilitre or below, pelvic lymph node metastases predominated—spread confined to the regional drainage basins around the prostate. In contrast, patients with ISUP grades 4 to 5 and initial PSA above 50 nanograms per millilitre were far more likely to harbour distant metastases, the true game-changers in treatment planning, since they shift management from curatively intended surgery or radiotherapy toward systemic therapy. The pattern echoes the biological logic of tumour progression: increasingly disorganised, high-grade tumours paired with heavy tumour burden, reflected in soaring PSA, are more capable of seeding far-flung sites.

The team also examined whether the scanner’s own quantitative output could substitute for pathology. The maximum standardised uptake value, SUVmax, which reflects the peak concentration of the radiotracer in the primary tumour, correlated strongly with ISUP grade, with a correlation coefficient of 0.61. Yet the authors caution that SUVmax was not a reliable surrogate marker for aggressiveness. The correlation, while robust statistically, is too loose to replace histopathological grading, whose tissue-based assessment captures architectural and nuclear features that tracer uptake only approximates. The finding is a reminder of a broader lesson in molecular imaging: quantitative biomarkers complement but do not supplant the pathologist’s verdict on biopsy material.

The implications reach well beyond the German centres where the data were collected. In the United States, Europe, and Australia, PSMA PET/CT is increasingly embedded in guidelines for high-risk disease, but in much of Asia, Africa, Latin America, and Eastern Europe, PET capacity remains a bottleneck. Technetium-99m, the isotope used in this study, is produced in widely distributed generator systems, requires no on-site cyclotron, and its SPECT cameras are already installed in thousands of nuclear medicine departments worldwide. When PSMA PET/CT is simply unavailable, the authors conclude, [99mTc]Tc-PSMA SPECT/CT may represent a valuable alternative for the primary staging of carefully selected prostate cancer patients—and the combined PSA-plus-ISUP criteria from this study supply exactly the selection logic that such an alternative needs to be used economically and effectively.

Of course, the study’s retrospective design and modest cohort of 91 patients mean the findings require prospective validation before they can be written into guidelines. Selection bias is possible, since the patients who received SPECT/CT may not represent the full spectrum of newly diagnosed disease, and detection thresholds derived from one tracer, one administered activity range, and one scanner generation may not transfer unchanged to other settings. The authors received no external funding for the work and declared relevant consultancy and lecture-fee relationships in the nuclear medicine industry. Still, the core message is likely to endure: the two numbers sitting at the top of every prostate cancer chart—the PSA value and the biopsy grade—together form a powerful pre-test probability engine. Used deliberately, they can direct PSMA imaging, whether by SPECT or PET, to the men most likely to benefit, sparing others an unnecessary scan while ensuring that metastatic disease, wherever it hides, is found before treatment plans are locked in.

Subject of Research: Patient selection criteria for primary staging of prostate cancer using [99mTc]Tc-PSMA SPECT/CT based on PSA level and ISUP grade

Article Title: Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease

Article References: Liepe, K., Hoang, T. M., Dietrich, I., Piechota, H.-J., & Baehr, M. (2026). Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08168-8

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08168-8

Keywords: prostate cancer, PSMA SPECT/CT, PSA, ISUP grade, primary staging, metastatic disease, [99mTc]Tc-MIP-1404, SUVmax, pelvic lymph node metastases, nuclear medicine, patient selection, molecular imaging

CPX-351 is not an ordinary chemotherapy combination. It encapsulates cytarabine and daunorubicin within liposomes at a fixed five-to-one molar ratio, allowing the two agents to be delivered together and to persist in the bloodstream for longer than conventional formulations. This pharmacokinetic profile improves drug uptake by leukaemic blasts and has demonstrated clinical benefit for patients whose disease arises from prior therapy or carries myelodysplasia-related genetic changes, groups that historically fared poorly with standard induction regimens. Because the drug can be administered in both inpatient and outpatient settings, clinicians have increasingly explored ambulatory delivery as a way to spare hospital beds, reduce exposure to nosocomial infections, and preserve patients’ autonomy during a demanding course of intensive treatment.

To formalize this practice, a steering group of nine haematologists with hands-on experience in outpatient CPX-351 treatment was assembled from institutions across Europe and Australia. The group drafted a series of consensus statements organized into six key domains covering patient selection, definitions of treatment settings, the anticipated benefits of outpatient care, patient and caregiver requirements, healthcare system prerequisites, and practical measures for optimizing delivery. Their statements were then subjected to validation by a much wider panel: an online survey of 200 haematologists drawn from Australia, France, Germany, Italy, the United Kingdom, and Spain, all of whom had experience with intensive chemotherapy and outpatient care for AML. Agreement was measured on a four-point Likert scale, with consensus defined as at least seventy-five percent agreement for each statement.

The results were strikingly decisive. Forty-two of the forty-three statements, ninety-eight percent of the total, achieved consensus, and thirty-one of them reached agreement levels of ninety percent or higher. Such near-unanimity among two hundred specialists spanning six countries and diverse healthcare systems is uncommon in Delphi studies and signals that the clinical community has converged on a coherent view of how outpatient CPX-351 delivery should be approached. High alignment emerged particularly around the identification of suitable patients and the definition of what constitutes an appropriate outpatient treatment setting, the foundational questions that determine whether a given individual can safely receive intensive liposomal chemotherapy without overnight admission to a hematology ward.

When it came to the benefits of outpatient treatment, the panel expressed its strongest agreement on potential advantages for hospital resourcing, an issue of acute relevance as many hematology units face chronic bed shortages. Respondents also strongly endorsed improvements in patients’ physical and psychological status and in quality of life, reflecting a broader movement in oncology toward care models that respect patients’ daily lives. For older or comorbid patients with t-AML or AML-MRC, who may already be coping with the consequences of prior malignancy treatment, the ability to undergo induction chemotherapy while sleeping in their own beds, staying connected to family, and avoiding the disorientation of prolonged hospitalization carries real therapeutic and emotional weight.

The consensus did not shy away from the prerequisites that make such a model viable. The survey highlighted significant agreement on key patient and caregiver requirements, including cognitive and physical abilities sufficient to recognize and report emerging problems, reliable communication channels with the treating team, and reasonable access to the hospital or an affiliated emergency facility. These criteria acknowledge the central paradox of ambulatory intensive chemotherapy: the treatment is administered outside the ward, but the risk of febrile neutropenia, bleeding, and other complications remains, so patients must be selected, educated, and supported with the same rigor applied to any inpatient induction regimen.

Healthcare system requirements formed another domain of strong agreement. Respondents emphasized the need for explicit hospital protocols, adequate available resources, and robust systems for managing complications when they arise. In practice, this means that outpatient CPX-351 programs cannot simply be layered onto existing services without investment. They demand dedicated staff training, clearly defined escalation pathways, rapid-access clinics or equivalent mechanisms for same-day assessment, and coordination across the multidisciplinary team, including haematologists, nurses, pharmacists, and emergency physicians who may encounter these patients between scheduled visits. The consensus framework effectively functions as a checklist for institutions considering launching such a service.

Beyond eligibility and infrastructure, the panel endorsed a set of practical measures to optimize day-to-day delivery. These included the use of patient assessment tools to standardize selection and monitoring, structured collection of patient feedback, ongoing staff education, deliberate coordination among multidisciplinary team members, and the systematic sharing of best practices across centers. Although the authors acknowledge that challenges may differ across countries and healthcare settings, with reimbursement structures, geographic distances, and staffing models varying widely, the consensus provides clear, transferable guidance on safe and effective outpatient administration. For centers with less experience in ambulatory delivery of CPX-351, the document offers a ready-made starting point grounded in the collective judgment of the international hematology community.

The significance of this work extends beyond a single drug. Intensive chemotherapy for acute myeloid leukaemia has traditionally been synonymous with weeks of hospitalization, a model that burdens patients, families, and health systems alike. As liposomal and targeted therapies broaden the options for older and frailer patients, and as ambulatory care models prove their worth in other malignancies, structured consensus documents like this one will play an increasingly important role in translating clinical trial evidence into safe everyday practice. The near-total agreement achieved here suggests that outpatient CPX-351 treatment for t-AML and AML-MRC is no longer an experimental convenience but an emerging standard of care, provided that centers adhere to the patient-selection criteria, monitoring requirements, and multidisciplinary safeguards that the international panel has now so clearly defined.

Subject of Research: Outpatient delivery of CPX-351 liposomal cytarabine-daunorubicin for therapy-related acute myeloid leukaemia and AML with myelodysplasia-related changes

Article Title: Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus

Article References: Mehta, P., Martínez-Roca, A., Cahalin, P., McNamara, C., Salamero, O., Martelli, M. P., Franke, G.-N., Capelli, D., de Andrés-Nogales, F., Francia, R., Lassman, E., & Conn, J. (2026). Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus. Annals of Hematology. https://doi.org/10.1007/s00277-026-07220-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07220-9

Keywords: CPX-351, acute myeloid leukaemia, t-AML, AML-MRC, liposomal cytarabine-daunorubicin, outpatient care, Delphi consensus, haematology, chemotherapy, ambulatory care, patient selection, quality of life